Pharmacology of antidepressants: selectivity or multiplicity?
The understanding of mechanisms of antidepressant action has evolved over time. The strong antidepressant activity of the tricyclic antidepressants (TCAs) has supported the role of both norepinephrine and serotonin (5-HT) in depression and the mechanism involved in antidepressant action. The next generation of antidepressants included the selective serotonin reuptake inhibitors (SSRIs), further supporting the role of serotonin, while the selective norepinephrine reuptake inhibitors such as maprotiline and reboxetine underlined the relevance of norepinephrine. These developments suggest that either facilitation of serotonin or norepinephrine or both may lead to an antidepressant response. The next step was the development of mixed serotonin-norepinephrine reuptake inhibitors (SNRIs), exemplified by venlafaxine and milnacipran. As with the TCAs, the antidepressant activity of SNRIs is based on inhibition of norepinephrine and serotonin reuptake, but unlike TCAs they do not have anticholinergic, antihistaminergic, and cardiotoxic effects. Although norepinephrine is known to stimulate serotonin cell firing rate via the alpha1-adrenoceptors, norepinephrine and serotonin have independent antidepressant actions. The latest development has been the introduction of the noradrenergic and specific serotonergic antidepressant mirtazapine. Its antidepressant effect appears to be related to dual enhancement of central noradrenergic and serotonergic neurotransmission by blockade of alpha2-adrenoceptors. In addition, mirtazapine directly blocks 5-HT2 and 5-HT3 receptors, which may account for its anxiolytic and sleep-improving properties as well as its lack of adverse events that are typical of SSRIs.
Westenberg
H G
HG
Department of Psychiatry, Utrecht Medical Center, The Netherlands.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000078785:Mirtazapine; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D009638:Norepinephrine / Q000502:physiology; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects; D011968:Receptors, Histamine / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000928:Antidepressive Agents; D008803:Mianserin; D000078785:Mirtazapine; D008996:Monoamine Oxidase Inhibitors; D014179:Neurotransmitter Uptake Inhibitors; D009638:Norepinephrine; D018341:Receptors, Adrenergic, alpha-2; D011968:Receptors, Histamine; D011976:Receptors, Muscarinic; D017981:Receptors, Neurotransmitter; D011985:Receptors, Serotonin; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors